The University of Southampton
University of Southampton Institutional Repository

The glycopeptide vancomycin does not enhance toll-like receptor 2 (TLR2) activation by Streptococcus pneumoniae

The glycopeptide vancomycin does not enhance toll-like receptor 2 (TLR2) activation by Streptococcus pneumoniae
The glycopeptide vancomycin does not enhance toll-like receptor 2 (TLR2) activation by Streptococcus pneumoniae

OBJECTIVES: The exposure of Streptococcus pneumoniae to cell-wall-active antibiotics in vivo and in vitro results in the release of bacterial components that can induce proinflammatory activation of human cells via toll-like receptor 2 (TLR2). The aim of this study was to compare the activation of human TLR2 pathways after exposure of S. pneumoniae to faropenem, cefotaxime and vancomycin.

MATERIALS AND METHODS: Streptococcus pneumoniae D39 was exposed to cefotaxime, faropenem or vancomycin for 6 h during lag or early log phase growth. IL-8 promoter activity of HeLa cells was measured using a dual luciferase reporter plasmid system. HeLa cells were transfected with an expression vector containing TLR2/CD14, or empty vector/CD14 and IL-8 promoter activity was measured using luminescence. Cells were stimulated with antibiotic-treated bacteria, untreated bacteria or medium-only controls.

RESULTS: Lag phase S. pneumoniae treated at sub-MIC (1/8 MIC) cefotaxime or faropenem induced 11-fold and 8-fold increases, respectively, in TLR2-mediated IL-8 promoter activity when compared with untreated bacteria. Early log MIC cefotaxime or faropenem-treated bacteria also enhanced TLR2 activation by 3-fold and 4-fold, respectively, when compared with untreated bacteria. Vancomycin treatment had no effect on TLR2 induction at any growth stage or MIC ratio tested.

CONCLUSIONS: beta-Lactam antibiotics induce surface changes and release of cell wall structures from bacteria that are proinflammatory via TLR2, but the glycopeptide vancomycin does not.

Anti-Bacterial Agents, Cefotaxime, Cell Wall, Cephalosporins, Genes, Reporter, HeLa Cells, Humans, Interleukin-8, Lactams, Lipopolysaccharide Receptors, Luciferases, Membrane Glycoproteins, Microbial Sensitivity Tests, Plasmids, Receptors, Cell Surface, Streptococcus pneumoniae, Toll-Like Receptor 2, Toll-Like Receptors, Transfection, Vancomycin, beta-Lactams, Journal Article, Research Support, Non-U.S. Gov't
0305-7453
76-78
Moore, Lisa J.
13095db5-12ee-47f4-ae09-b1deca4881d3
Pridmore, Alison C.
b704c202-afcc-4fde-9169-48e51f9fa0b0
Dower, Steven K.
c59b6ed1-57d4-49cb-815c-038a96601ecc
Read, Robert C.
b5caca7b-0063-438a-b703-7ecbb6fc2b51
Moore, Lisa J.
13095db5-12ee-47f4-ae09-b1deca4881d3
Pridmore, Alison C.
b704c202-afcc-4fde-9169-48e51f9fa0b0
Dower, Steven K.
c59b6ed1-57d4-49cb-815c-038a96601ecc
Read, Robert C.
b5caca7b-0063-438a-b703-7ecbb6fc2b51

Moore, Lisa J., Pridmore, Alison C., Dower, Steven K. and Read, Robert C. (2004) The glycopeptide vancomycin does not enhance toll-like receptor 2 (TLR2) activation by Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy, 54 (1), 76-78. (doi:10.1093/jac/dkh301).

Record type: Article

Abstract

OBJECTIVES: The exposure of Streptococcus pneumoniae to cell-wall-active antibiotics in vivo and in vitro results in the release of bacterial components that can induce proinflammatory activation of human cells via toll-like receptor 2 (TLR2). The aim of this study was to compare the activation of human TLR2 pathways after exposure of S. pneumoniae to faropenem, cefotaxime and vancomycin.

MATERIALS AND METHODS: Streptococcus pneumoniae D39 was exposed to cefotaxime, faropenem or vancomycin for 6 h during lag or early log phase growth. IL-8 promoter activity of HeLa cells was measured using a dual luciferase reporter plasmid system. HeLa cells were transfected with an expression vector containing TLR2/CD14, or empty vector/CD14 and IL-8 promoter activity was measured using luminescence. Cells were stimulated with antibiotic-treated bacteria, untreated bacteria or medium-only controls.

RESULTS: Lag phase S. pneumoniae treated at sub-MIC (1/8 MIC) cefotaxime or faropenem induced 11-fold and 8-fold increases, respectively, in TLR2-mediated IL-8 promoter activity when compared with untreated bacteria. Early log MIC cefotaxime or faropenem-treated bacteria also enhanced TLR2 activation by 3-fold and 4-fold, respectively, when compared with untreated bacteria. Vancomycin treatment had no effect on TLR2 induction at any growth stage or MIC ratio tested.

CONCLUSIONS: beta-Lactam antibiotics induce surface changes and release of cell wall structures from bacteria that are proinflammatory via TLR2, but the glycopeptide vancomycin does not.

Full text not available from this repository.

More information

Published date: July 2004
Keywords: Anti-Bacterial Agents, Cefotaxime, Cell Wall, Cephalosporins, Genes, Reporter, HeLa Cells, Humans, Interleukin-8, Lactams, Lipopolysaccharide Receptors, Luciferases, Membrane Glycoproteins, Microbial Sensitivity Tests, Plasmids, Receptors, Cell Surface, Streptococcus pneumoniae, Toll-Like Receptor 2, Toll-Like Receptors, Transfection, Vancomycin, beta-Lactams, Journal Article, Research Support, Non-U.S. Gov't

Identifiers

Local EPrints ID: 416421
URI: https://eprints.soton.ac.uk/id/eprint/416421
ISSN: 0305-7453
PURE UUID: 16bf030d-bc70-44b3-8fdf-163b375ab4ab
ORCID for Robert C. Read: ORCID iD orcid.org/0000-0002-4297-6728

Catalogue record

Date deposited: 15 Dec 2017 17:30
Last modified: 14 Mar 2019 01:36

Export record

Altmetrics

Contributors

Author: Lisa J. Moore
Author: Alison C. Pridmore
Author: Steven K. Dower
Author: Robert C. Read ORCID iD

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×